| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/20/2001 | WO2001095929A2 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | WO2001095928A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | WO2001095924A2 Method for treating a movement disorder |
| 12/20/2001 | WO2001095920A1 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 12/20/2001 | WO2001095907A1 Pharmaceutical composition for the treatment of multiple sclerosis |
| 12/20/2001 | WO2001095899A2 Pharmaceutical compositions comprising cannabidiol derivatives |
| 12/20/2001 | WO2001095898A1 Analgesic and anti-inflammatory compositions containing cox-2 inhibitors |
| 12/20/2001 | WO2001095893A1 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095892A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095859A2 Novel heterocyclic analogs of diphenylethylene compounds |
| 12/20/2001 | WO2001095785A2 Modulation of immune response and methods based thereon |
| 12/20/2001 | WO2001095709A1 Mouse showing neurofibril change due to senile dementia |
| 12/20/2001 | WO2001088108A8 Neuronal serine-threonine protein kinase |
| 12/20/2001 | WO2001087838A8 Cyclohexane derivatives and their use as therapeutic agents |
| 12/20/2001 | WO2001058896A8 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 12/20/2001 | WO2001055725A3 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 12/20/2001 | WO2001049689A3 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM |
| 12/20/2001 | WO2001044207A3 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 12/20/2001 | WO2001034120B1 Apparatus and method for preparing microparticles using in-line solvent extraction |
| 12/20/2001 | WO2001019770A3 Rxr modulators with improved pharmacologic profile |
| 12/20/2001 | WO2001015693A3 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 12/20/2001 | WO2001010426A3 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 12/20/2001 | WO2001002552A3 Double transgenic animals as models for neurodegenerative disease |
| 12/20/2001 | WO2000072834A9 Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| 12/20/2001 | WO2000072832A3 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts |
| 12/20/2001 | WO2000068387A3 Nucleic acids and proteins with interferon-beta activity |
| 12/20/2001 | WO1997049394A3 Sold oral dosage forms of valsartan |
| 12/20/2001 | US20010053799 New treatments using venlafaxine |
| 12/20/2001 | US20010053793 Administering dehydroascorbic acid |
| 12/20/2001 | US20010053790 Mothod and composition for treatment of ischemic neuronal reperfusion injury |
| 12/20/2001 | US20010053788 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
| 12/20/2001 | US20010053783 Central nervous system disorders |
| 12/20/2001 | US20010053782 Pyrrolo[2,3-d]pyrimidine compounds |
| 12/20/2001 | US20010053777 Synergistic mixture containing alpha 2-antagonist agent and neuropsychic drug |
| 12/20/2001 | US20010053764 Interleukin-1 inhibitors in the treatment of diseases |
| 12/20/2001 | US20010053763 Method and composition for modulating an immune response |
| 12/20/2001 | US20010053536 cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor |
| 12/20/2001 | US20010053533 Detecting infectious protein in solution; prepare solution composed from body fluid or fluidized organ expose to chromatographic column, detect infectious protein |
| 12/20/2001 | US20010053386 (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one maleate |
| 12/20/2001 | US20010053370 Parkinson's disease treatment |
| 12/20/2001 | US20010053369 Treating a movement disorder by intracranial administration of a neurotoxin, especially a botulinium toxin |
| 12/20/2001 | US20010053364 Treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion; relieving pain associated with smooth muscle disorders, including spasms in the sphincter muscles; type A & B toxins |
| 12/20/2001 | US20010053363 Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors |
| 12/20/2001 | US20010053357 Peptide having an amino acid sequence corresponding to an amino acid sequence of a V-domain of a receptor for advanced glycation endproduct. |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | DE10027383A1 Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz Nucleic acid molecule comprising a sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide nucleic acid sequence |
| 12/20/2001 | DE10024171A1 Neuronale Serin-Threonin-Protein-Kinase Neuronal serine threonine protein kinase |
| 12/20/2001 | CA2413077A1 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | CA2412979A1 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | CA2412843A1 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 12/20/2001 | CA2412632A1 Hmg-coa reductase inhibitors and method |
| 12/20/2001 | CA2412579A1 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | CA2412216A1 Lactam inhibitors of factor xa and method |
| 12/20/2001 | CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | CA2411811A1 Sulfonamide derivatives |
| 12/20/2001 | CA2411472A1 Cd154 variants |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2410171A1 Novel heterocyclic analogs of diphenylethylene compounds and uses thereof |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/20/2001 | CA2407699A1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/19/2001 | EP1164141A2 Opioid peptides and their use for treatment of pain |
| 12/19/2001 | EP1164134A1 Benzimidazole compounds and their use as modulators of the GABA A receptor complex |
| 12/19/2001 | EP1163908A1 Water-soluble complex of an extract of Ginkgo Bilboa, process for the preparation thereof and composition comprising the same |
| 12/19/2001 | EP1163907A1 Use of l-threo-methylphenidate for the treatment of depression |
| 12/19/2001 | EP1163902A2 Transdermal preparation containing hydrophilic or salt-form drug |
| 12/19/2001 | EP1163522A1 Method for detecting superantigen activity in a biological sample |
| 12/19/2001 | EP1163356A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites |
| 12/19/2001 | EP1163336A2 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 12/19/2001 | EP1163335A1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION |
| 12/19/2001 | EP1163332A1 48 human secreted proteins |
| 12/19/2001 | EP1163331A1 50 human secreted proteins |
| 12/19/2001 | EP1163271A1 Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders |
| 12/19/2001 | EP1163270A1 Dihydroouabain-like factor and diagnostic and therapeutic compositions and methods |
| 12/19/2001 | EP1163255A1 50 human secreted proteins |
| 12/19/2001 | EP1163241A1 Zolpidem salts |
| 12/19/2001 | EP1163239A1 Modified amino-acid amides as cgrp antagonists |
| 12/19/2001 | EP1163237A1 Amide derivatives |
| 12/19/2001 | EP1163236A1 Aromatic heterocyclic compounds as anti-inflammatory agents |
| 12/19/2001 | EP1163226A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 12/19/2001 | EP1163225A1 Compounds and methods for modulation of estrogen receptors |
| 12/19/2001 | EP1163221A1 Sulfonamide derivatives as 5ht7 receptor antagonists |
| 12/19/2001 | EP1163220A1 Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist |
| 12/19/2001 | EP1163214A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 12/19/2001 | EP1163213A1 Hydroxamic and carboxylic acid derivatives |
| 12/19/2001 | EP1163212A1 Amide derivatives |
| 12/19/2001 | EP1163208A2 Caspase inhibitors and uses thereof |
| 12/19/2001 | EP1163029A2 Nitrate esters and their use for inducing neuroprotection and cognition enhancement |
| 12/19/2001 | EP1163006A1 Method to prevent xenograft transplant rejection |
| 12/19/2001 | EP1163003A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist |
| 12/19/2001 | EP1162988A1 Wafer delivery system |
| 12/19/2001 | EP1162972A2 Devices and methods for pain management |
| 12/19/2001 | EP1162970A2 Anti-inflammatory uses of manzamines |
| 12/19/2001 | EP1162967A1 The use of certain affinity nmda antagonists as antidepressants |
| 12/19/2001 | EP1162960A2 Pharmaceutical compositions for the treatment of posttraumatic stress disorder |
| 12/19/2001 | EP1162959A2 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
| 12/19/2001 | EP1162946A1 Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained |
| 12/19/2001 | EP1123100A4 Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof |
| 12/19/2001 | EP1094816A4 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 12/19/2001 | EP1033978B1 Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
| 12/19/2001 | EP0847391B1 Aromatic compounds and pharmaceutical compositions containing them |